Instalab

ALMI Test

One of the strongest predictors of future frailty and disability, more revealing than weight or BMI alone.

Who benefits from ALMI testing

Going Through or Past Menopause
Estradiol decline accelerates muscle loss in midlife. This scan shows whether you are losing ground or holding steady.
Taking a Weight Loss Medication
GLP-1 agonists reduce lean mass alongside fat. This test shows whether your weight loss is the kind you actually want.
Pushing Past 50 and Staying Ahead
Muscle loss starts well before frailty becomes obvious. A baseline now gives you years of warning before mobility starts to slip.
Training Seriously for Strength
Get objective feedback on whether your training and protein intake are actually building the muscle you think they are.

About ALMI

Your weight on the scale tells you almost nothing about what your body is made of. Two people at the same height and weight can carry vastly different amounts of muscle, and that difference quietly determines who stays mobile and independent into their 70s and 80s and who does not.

ALMI (appendicular lean mass index) measures the muscle in your arms and legs scaled to your height, captured by a low-dose body composition scan called DXA (dual-energy X-ray absorptiometry). It is the muscle you use to walk, climb stairs, lift groceries, and catch yourself when you stumble. Falling below the established cutoffs is one of the clearest early signals you are heading toward frailty and loss of independence.

Mortality and Disability

Low ALMI sits at the center of the diagnosis of sarcopenia, the age-related loss of muscle that drives much of late-life frailty. In a pooled analysis of about 26,625 older adults from nine cohorts, men with appendicular lean mass below 19.75 kg or women below 15.02 kg were considerably more likely to have clinically meaningful weakness. In about 1,487 prefrail and frail older adults, those with higher appendicular lean mass had a lower risk of dying over follow-up.

The signal is strongest when low muscle mass is paired with low grip strength or slow walking speed. Low ALMI on its own is a yellow flag. Low ALMI alongside weakness or slow gait is the actual sarcopenia diagnosis, and that combination predicts mobility loss and mortality far better than any single measure.

Type 2 Diabetes

More muscle relative to body size means better blood sugar control. In about 1,893 middle-aged adults followed for 10 years in the CARDIA study, those with more appendicular lean mass relative to BMI had a lower incidence of type 2 diabetes, with most of the protective effect mediated through lower waist circumference. Genetic studies using Mendelian randomization (a technique that uses inherited variants to mimic a randomized trial) suggest higher appendicular lean mass is causally linked to lower diabetes risk.

Stroke and Alzheimer's Risk

Higher appendicular lean mass appears to lower the risk of ischemic stroke (stroke caused by a blocked blood vessel) and Alzheimer's disease, according to a Mendelian randomization study. The protective effect held for both large-artery and small-vessel stroke subtypes. In about 2,704 older men in the Health ABC study, lower appendicular lean mass and lower grip strength were both linked to a higher risk of developing dementia over follow-up.

Bone Health and Osteoporosis

Muscle and bone rise and fall together. In about 1,418 postmenopausal women with type 2 diabetes, higher appendicular lean mass was independently protective against osteoporosis. In about 100 young men and 160 postmenopausal women, higher ALMI tracked with greater bone area and stronger trabecular bone (the spongy inner bone that absorbs shock). If you are at high fracture risk, knowing your ALMI adds context that a bone density scan alone cannot give you.

Lung Function

In about 1,489 children and adolescents, higher muscle mass was associated with better forced expiratory and static lung function, while higher fat mass was linked to worse lung function. In about 687 adults with asthma referred for pulmonary rehabilitation, low appendicular lean mass and sarcopenic obesity (low muscle paired with high fat) were both linked to worse exercise capacity, weaker quadriceps, and lower maximal oxygen uptake.

Reference Ranges

The cutoffs below come from large DXA studies of European and North American adults. Different DXA machines (GE Lunar, Hologic) and different populations produce different numbers. Use these as orientation, not a universal target, and compare your results within the same lab and same machine over time for the most meaningful trend.

SourceMenWomenWhat it suggests
EWGSOP2 (European, DXA)≤7.0 kg/m²≤5.5 kg/m²Low muscle mass, supports a sarcopenia diagnosis
FNIH absolute ALM<19.75 kg<15.02 kgIdentifies adults with clinically meaningful weakness
FNIH ALM/BMI ratio<0.789<0.512Body-size adjusted; better predicts mobility loss

Sources: EWGSOP2 cutpoints from the 2019 consensus update; FNIH cutpoints from Cawthon 2014 and McLean 2014.

Why Adjusting for Body Fat Matters

You might expect that more muscle is always better, period. The data are messier than that. Several large studies show that ALM/BMI or ALM adjusted for fat predicts disability, mortality, and metabolic risk better than raw ALMI alone. This is not because muscle stops mattering. It is because raw ALMI looks deceptively reassuring in someone who has high muscle but also high fat, a combination called sarcopenic obesity.

Think of ALMI as a phenotype indicator rather than a simple good-number / bad-number marker. A normal raw ALMI with a low ALM/BMI is a different problem than a low raw ALMI in a thin frame, and they need different action plans. If your raw ALMI looks fine but your ALM/BMI is low, you may still be carrying too little muscle for your size and still face elevated risk.

Tracking Your Trend

A single ALMI reading tells you where you stand against population averages. The trend tells you what your body is actually doing. Get a baseline scan, retest at 6 months if you are starting strength training, recovering from significant weight loss, or beginning a GLP-1 medication, then scan annually. Pay attention to the direction more than the absolute number. Losing 0.2 kg/m² per year while staying inside the normal range is a different problem than holding steady at the lower end.

Use the same DXA machine for serial scans whenever possible. Cross-machine comparisons can introduce more variability than the actual biological change you are trying to detect.

What to Do If Your ALMI Is Low

A low ALMI on its own is not a diagnosis. Pair the result with two simple companion measures: grip strength using a handheld dynamometer and gait speed timed over a short walk. Low ALMI with normal grip and normal gait speed is a watch-list situation that warrants strength training and a protein intake review. Low ALMI alongside weak grip or slow walking meets the criteria for sarcopenia and warrants action: a referral to a physiatrist, geriatrician, or sports medicine physician, plus a structured progressive resistance training program. If you are on or considering a GLP-1 medication for weight loss, a low ALMI changes the calculus toward including resistance training and higher protein intake from day one.

When Results Can Be Misleading

  • Recent meal: A small meal before scanning produces small but measurable shifts in DXA body composition estimates. An overnight fast is preferred for the cleanest reading.
  • Hydration: Significant dehydration or fluid overload can shift estimated lean mass without any real change in muscle.
  • Different machines: GE Lunar and Hologic DXA scanners produce systematically different numbers. Track your trend on the same machine.
  • High BMI: At very high BMI, raw ALMI can look reassuring even when functional muscle relative to body size is low. Always look at ALM/BMI alongside raw ALMI in this case.

What Moves This Biomarker

Evidence-backed interventions that affect your ALMI level

Increase
Lifelong strength or sprint training
Sustained resistance and sprint training preserves ALMI and lowers the prevalence of sarcopenic obesity. In a study of 256 men comparing lifelong strength athletes, sprint athletes, endurance athletes, and untrained age-matched controls, strength athletes maintained the highest muscle mass and sprint and endurance athletes maintained low fat mass into older age. The takeaway: ongoing heavy resistance training is the most reliable way to keep your ALMI in a protective range as you get older.
ExerciseStrong Evidence
Increase
Staying physically active through the menopause transition
Higher physical activity during the years around menopause partially blunts the muscle loss that normally accompanies estradiol decline. In a study of about 1,393 middle-aged Finnish women, those with higher physical activity through perimenopause and early postmenopause maintained more skeletal muscle mass than less active peers. If you are in or approaching menopause, this is the highest-yield window to lock in strength habits.
ExerciseModerate Evidence
Decrease
High-potency GLP-1 receptor agonists (tirzepatide, semaglutide) without resistance training
Potent GLP-1 receptor agonists used for weight loss reduce both fat and lean mass, and the lean mass loss is large enough to lower ALMI. A network meta-analysis of randomized trials found tirzepatide and semaglutide caused significant reductions in lean mass alongside the larger fat loss. If you are taking these medications, the lean mass drop is real, and pairing the medication with progressive resistance training and adequate protein is the standard mitigation strategy.
MedicationModerate Evidence
Decrease
Significant unintentional or rapid weight loss without strength training
When weight comes off without a resistance training stimulus, a meaningful portion comes from muscle. In an NHANES analysis of about 4,984 older adults, self-reported weight gain was tied to a higher risk of meeting low lean mass criteria over time, and weight loss without other interventions was also associated with meaningful lean mass shifts. The point is not to avoid losing fat. The point is to load your muscles while you do it so the loss is fat, not lean tissue.
LifestyleModerate Evidence

Frequently Asked Questions

Related Tests

ALMI is best interpreted alongside these tests.

References

25 studies
  1. Cawthon P, Peters K, Shardell M, Mclean R, Dam TT, Kenny a, Fragala M, Harris T, Kiel D, Guralnik J, Ferrucci L, Kritchevsky S, Vassileva M, Studenski S, Alley DThe Journals of Gerontology Series a2014
  2. Mclean R, Shardell M, Alley D, Cawthon P, Fragala M, Harris T, Kenny a, Peters K, Ferrucci L, Guralnik J, Kritchevsky S, Kiel D, Vassileva M, Xue Q, Perera S, Studenski S, Dam TTThe Journals of Gerontology Series a2014
  3. Tessier AJ, Wing S, Rahme E, Morais J, Chevalier SJournal of Cachexia, Sarcopenia and Muscle2019
  4. Brown JC, Harhay MO, Harhay MNThe Journal of Nutrition, Health & Aging2016
  5. Walker S, Von Bonsdorff M, Cheng S, Hakkinen K, Bondarev D, Heinonen a, Korhonen MFrontiers in Sports and Active Living2023